Pharmaceuticals News and Research

RSS

Improving healthcare sustainability through carbon data

Healthcare sustainability data can identify emissions hotspots and improve operational decision-making across healthcare and life sciences.

From Nocomed 9 Oct 2026

Universal germline genetic testing catches missed cancer risks in older patients

Universal germline genetic testing of nearly 40,000 patients with solid tumors detected a substantial proportion of inherited gene variants that would have been missed by the standard germline testing approach that excludes those over age 50.

8 Oct 2026

Terumo announces global commercial launch of K-Pack Embrace™ active safety needle

Terumo Corporation today announced the global commercial launch of its K-Pack Embrace™ active safety needle.

From Terumo Corporation 6 Oct 2026

BioDuro appoints Greg Makara as Senior Vice President Lead Discovery Chemistry to strengthen early drug discovery capabilities

BioDuro, a global integrated contract research, development and manufacturing organization (CRDMO), today announced the appointment of Greg Makara, Ph.D., as Senior Vice President Lead Discovery Chemistry.

From BioDuro 5 Oct 2026

Portable paper device rapidly detects scopolamine in beverages

Isabel Poves, researcher at the University of the Basque Country-EHU, has developed a microfluidic paper-based device that provides a rapid, reliable and easy way to detect scopolamine and related compounds.

1 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026

Triple combination therapy trial for HR+/HER2− breast cancer halts early due to toxicity concerns

HR+/HER2− breast cancer constitutes approximately 65–75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up to 60% of patients derive no clinical benefit from these agents, underscoring the urgent need for more effective therapeutic strategies.

28 Sep 2026

Intentional substance exposures at school rise sharply among younger children

A new study found that rates of intentional substance exposures at school reported to U.S. poison centers increased substantially among elementary- and middle-school-aged children from 2000 through 2024, while high-school-aged adolescents continued to experience the highest rates of serious medical outcomes and hospital admissions.

28 Sep 2026

Study links insomnia to higher stroke and hospitalization risks

Insomnia is associated with a 26% higher risk of stroke and 28% higher odds of hospital admission, according to new research in Sleep Medicine Reviews. The researchers say the findings support recognizing insomnia as an important marker of brain, mental and general health.

28 Sep 2026

New study tracks rising heart and kidney risks in people with type 2 diabetes

The risk of developing chronic kidney disease (CKD) or heart failure (HF), or dying, following a type 2 diabetes (T2D) diagnosis increases substantially over time, according to new research being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

27 Sep 2026

New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients

The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by reducing the risk of recurrence.

24 Sep 2026

Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases

A review in Cell Reports Medicine examines how advances in oligonucleotide chemistry and delivery have established ASOs and RNA interference therapies as a class of genetic medicines, with 21 oligonucleotides approved at the time of writing. It also identifies extrahepatic delivery, safety, target validation, individualized treatment, and data quality as priorities as the field expands into common diseases and explores AI-assisted development.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

Submicron IR for pharmaceutical research, development, and quality

The pharmaceutical and biopharmaceutical industries increasingly require rapid, accurate, and high-resolution analytical tools to characterize complex materials, ensure product quality, and accelerate innovation.

From Photothermal Spectroscopy Corp 22 Sep 2026

Experimental RNA therapy enhances weight loss while preserving lean muscle

GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain their weight - primarily as fat.

21 Sep 2026

Study defines early-onset cirrhosis caused by fatty liver disease

Researchers at University of California San Diego School of Medicine have published the first study to define early-onset cirrhosis caused by metabolic dysfunction-associated steatotic liver disease (MASLD), a condition known as fatty liver disease.

16 Sep 2026

Study links processed foods to targeted domain-specific cognitive decline

An unhealthy Western-style diet was associated with a faster cognitive decline in people with a genetic risk of Alzheimer's disease, according to new research led by Murdoch University and Alzheimer's Research Australia.

15 Sep 2026

Strength training shows no added arrhythmia risk in people with arrhythmogenic cardiomyopathy

People living with arrhythmogenic cardiomyopathy (ACM), a heritable heart condition that can significantly increase risks for sudden cardiac death, are advised to avoid high-intensity aerobic exercise.

10 Sep 2026

New blood screening algorithm reduces unnecessary Alzheimer's PET scans

A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial, according to research from scientists at the Keck School of Medicine of USC published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

9 Sep 2026